Jump to content

Novel imaging program for the detection of Lung Cancer

Recommended Posts

- CeMinesTM and Colorado Heart & Body Imaging form Strategic Alliance

http://www.medicalnewstoday.com/medical ... wsid=31100

Category: Lung Cancer News

Article Date: 25 Sep 2005

CeMines, Inc. announced that it has entered into a clinical research and product distribution agreement with Denver-based Colorado Heart & Body Imaging, LLC (CHBI), a recognized leader in the early detection of cancer, heart disease and osteoporosis. The agreement provides CHBI the opportunity to use CeMines' CellCorrectTMLAb Detection Test Kitsin upcoming clinical studies that relate patient serum biomarkers and imaging in diverse and healthy population groups.

The CeMines CellCorrectTMLAbkit detects altered autoimmunity and associated patterns (i.e., CeMines Molecular FingerPrintingTM) of lung cancer-related autoantibodies present in the bloodstream.

CeMines has conducted extensive international clinical studies which have consistently demonstrated that specific and unique patterns of certain human antibodies have regularly proven their utility as composite biomarkers to characterize lung cancer-and can therefore be used as a tool, complementing other technologies such as imaging, for use in lung cancer diagnosis.

CeMines uses a proprietary (patent-pending) bioinformatics-based pattern-recognition platform called CeMines Molecular FingerPrintingTM.

The Company's extensive proprietary cancer biomarker libraries are used to evaluate not only the presence or absence of autoantibody biomarkers, but have been further optimized to detect patterns of specific antibodies, useful in profiling cancers.

Roger Attick, CEO of CeMines, stated; “Physicians today have very limited choices of minimally invasive testing as a tool for use in diagnosis of lung cancer at an earlier stage. The alliance between CeMines and CHBI has the potential to create a ‘best in class' diagnostic protocol. When evaluated with CHBI advanced imaging, CellCorrect LAbblood testing based on CeMines Molecular FingerPrintingTMprovides complementary physiological data, thus enabling CHBI physicians to be more precise in analysis of anomalies detected during cardio pulmonary imaging.”

“As the nation's most technologically advanced and versatile screening center, we are proud to add the CellCorrectLAb test to our impressive arsenal of 'best of breed' early detection technologies,” reported James Ehrlich, M.D., medical director and founder of Colorado Heart and Body Imaging.

With regard to lung cancer, our nation's leading cancer killer, Ehrlich stated, “I am confident that early detection efforts, combining electron beam tomographic (EBT) imaging with CellCorrectLAbspecific serum biomarkers, should favorably change the prognosis for thousands.”

About CeMines, Inc.

CeMines, Inc. is a Life Sciences company specializing in molecular biology, research and development that is principal to commercialization of novel clinical products for worldwide use in diagnosis, treatment and prevention of cancer. The company was founded in 2000 by Dr. Toomas Neuman, Ph.D., Dr. Kaia Palm, Ph.D., and Mr. Richard Cavalli. Company headquarters are located in Golden, Colorado. CeMines' Diagnostics and Therapeutics Research & Development is located in La Jolla, California, and the company's European Union-based subsidiary of CeMines International, CeMines Estonia OÜ, is located in Tallinn, Estonia. http://www.cemines.com

About Colorado Heart and Body Imaging, LLC

Colorado Heart and Body Imaging utilizes breakthrough noninvasive technologies from around the globe in the early detection, diagnosis and prevention of cardiovascular disease, various cancers, sleep apnea, osteoporosis and stroke. Founded in 1997 by its medical director Dr. James Ehrlich, the company maintains two facilities in Denver and has developed numerous associations with physicians and specialty medical groups nationwide and regionally. Clinical preventive programs, executive assessments and research form the major activities of the corporation. Dr. Ehrlich, the president of the Society for Responsible Preventive Imaging, is also the chief medical officer of US Preventive Medicine and maintains a clinical appointment at the University of Colorado Health Sciences Center in Denver and the George Washington University School of Medicine in Washington DC. http://www.coloradoheart.com

Forward-Looking Statements

Any statements in this press release about future expectations, plans or prospects for the company, including the company's expectations and plans to complete the FDA review and clearance process for CellCorrectLAbconstitute Forward Looking statements. These statements involve risks and uncertainties which may cause results to differ materially from those set forth in these and previous statements. Forward-looking statements should be evaluated along with other information released by the company.



Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.